Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

BostonGene to Present Multiple Abstracts at the 2019 American Society of Hematology (ASH) Annual Meeting

BostonGene Corporation (BostonGene), a Boston-based biomedical software company, today announced that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida. In addition, BostonGene will exhibit at booth #152 in Hall B.

The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.


Sunday, December 8, 2019: 6:00 PM - 8:00 PM in Hall B, Level 2


Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2

Additional information on abstracts for the ASH Annual Meeting can be found here: https://www.hematology.org/Annual-Meeting/.

"We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year's ASH event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients' chances for survival," said Andrew Feinberg, President & CEO at BostonGene.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene's unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

These press releases may also interest you

at 02:00
The Food Equity Initiative and Knoq, have created a "no-contact" specialty delivery service to deliver allergy-free foods to families in need during the Coronavirus outbreak. The COVID-19 pandemic is increasing food insecurity by interrupting income,...

9 avr 2020
Joe's Gluten-Free Foods is recalling Joe's Gluten-Free Foods brand Potato & Onion Perogies from the marketplace because they contain milk which is not declared on the label. People with an allergy to milk should not consume the recalled product...

9 avr 2020
Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced it launched the COVID-19 Clinical Trials Alliance to connect sites, sponsors and CROs to accelerate COVID-19 trials required...

9 avr 2020
There has been a lot of talk about ventilators and N95 masks, but CRIMADI has observed the reality is that healthcare workers are struggling with a much longer list of shortages every day. And feeling helpless in being able to save as many lives as...

9 avr 2020
The International Sleep Products Association (ISPA) today announced that US mattress manufacturing facilities across the country are working hard to produce and deliver mattresses and other critical products to fellow Americans in need. ...

9 avr 2020
Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody (mAb) program. "We are proud...

News published on 21 november 2019 at 10:25 and distributed by: